162 related articles for article (PubMed ID: 11995359)
1. Adverse effects of azathioprine in the treatment of inflammatory bowel disease.
Martínez F; Nos P; Pastor M; Garrigues V; Ponce J
Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
[TBL] [Abstract][Full Text] [Related]
4. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
[TBL] [Abstract][Full Text] [Related]
5. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
6. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
8. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease.
Hindorf U; Johansson M; Eriksson A; Kvifors E; Almer SH
Aliment Pharmacol Ther; 2009 Mar; 29(6):654-61. PubMed ID: 19183142
[TBL] [Abstract][Full Text] [Related]
9. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP
Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine in inflammatory bowel disease, a safe alternative?
Tanis AA
Mediators Inflamm; 1998; 7(3):141-4. PubMed ID: 9705598
[TBL] [Abstract][Full Text] [Related]
12. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
13. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
14. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Shah JA; Edwards CM; Probert CS
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
[TBL] [Abstract][Full Text] [Related]
15. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease.
Ananthakrishnan AN; Attila T; Otterson MF; Lipchik RJ; Massey BT; Komorowski RA; Binion DG
J Clin Gastroenterol; 2007 Aug; 41(7):682-8. PubMed ID: 17667053
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
17. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine dose escalation in inflammatory bowel disease.
Rayner CK; Hart AL; Hayward CM; Emmanuel AV; Kamm MA
Aliment Pharmacol Ther; 2004 Jul; 20(1):65-71. PubMed ID: 15225172
[TBL] [Abstract][Full Text] [Related]
19. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
Mossop H; Davies P; Murphy MS
J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):123-9. PubMed ID: 18664861
[TBL] [Abstract][Full Text] [Related]
20. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases.
Weersma RK; Peters FT; Oostenbrug LE; van den Berg AP; van Haastert M; Ploeg RJ; Posthumus MD; Homan van der Heide JJ; Jansen PL; van Dullemen HM
Aliment Pharmacol Ther; 2004 Oct; 20(8):843-50. PubMed ID: 15479355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]